Pharmacoeconomic studies of asthma controller drugs: Marketing gimmick or icing on the cake?

Pharmacotherapy

Volumn 22, Issue 2 I, 2002, Pages 131-133

  Hendeles, Leslie ^a   Segal, Richard ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG COST; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOTHERAPY; MANAGED CARE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036151521     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.3.131.33555     Document Type: Editorial

References (10)

1. Montelukast: Data from clinical trials in the management of asthma
2. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma
3. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial
4. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial
5. Fluticasone propionate versus zafirlukast: Effect in patients previously receiving inhaled corticosteroid therapy
6. Comparison of patients' compliance with prescribed oral and inhaled asthma medications
7. Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions
8. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma
9. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population